Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)

Arkaitz Imaz; Jordi Niubó; Alieu Amara; Saye Khoo; Elena Ferrer; Juan M Tiraboschi; Laura Acerete; Benito Garcia; Antonia Vila; Daniel Podzamczer

首页> 外文期刊>Journal of neurovirology >Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)

【24h】

Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)

机译：脑脊液液体浓度和病毒抑制在HIV-1感染患者中接受Ritonavir-Boosted Atazanavir Plus Lamivudine双抗逆转录病毒治疗（西班牙艾滋病毒/艾滋病研究网络，Prec / Ris 39）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

This study aimed to assess cerebrospinal fluid (CSF) drug concentrations and viral suppression in HIV-1-infected patients on ritonavir-boosted atazanavir (ATV/r) plus lamivudine (3TC) dual therapy. HIV-1-infected adults with suppressed plasma HIV-1 RNA who switched to ATV/r plus 3TC were studied. Total ATV and 3TC concentrations at the end of the dosing interval (C~(24h)), using a validated LC-MS/MS method, and HIV-1 RNA were measured in paired CSF and plasma samples 12?weeks after switching. Ten individuals were included. Median (range) age was 42.5 (33–70) years, time on ART was 39.5 (11–197) months, and time with plasma HIV-1 RNA

机译：本研究旨在评估脑脊液（CSF）药物浓度和病毒抑制在Ritonavir-Boosted Atazanavir（ATV / R）加上拉米夫定（3TC）双重治疗的患者中的HIV-1感染患者。研究了与切换到ATV / R加3TC的抑制血浆HIV-1 RNA的HIV-1感染的成人。使用经过验证的LC-MS / MS方法的剂量间隔（C〜（24H））的总ATV和3TC浓度，并在配对的CSF和血浆样品中测量HIV-1 RNA 12.切换后的数周。包括十个人。中位数（范围）年龄为42.5（33-70）岁，艺术时间为39.5（11-197）个月，血浆HIV-1 RNA <α40拷贝/ ml的时间为15.5（6-46）个月。在基线时，所有患者中CSF HIV-1 RNA <α40拷贝/ ml。切换到ATV / R加3TC后12周，在9/10患者中，HIV-1 RNA在血浆和CSF中留下<α40拷贝/ mL。次优粘附到艺术的一名患者在血浆和CSF中呈现HIV-1 RNA反弹。 ATV和3TC的中值CSF - 血浆浓度比分别为0.013和0.417。 CSF中的中位数ATV C〜（24H）为10.4（3.7-33.4）Ng / ml（体外ATV IC〜（50）范围，1-11μg/ mL）。 CSF中的中位3TC C〜（24H）为43.4（16.2-99.3）Ng / ml（体外3TC IC〜（50）范围，0.68-20.6？ng / ml）。尽管CSF ATV C〜（24h）靠近或内部的CSF ATV C〜（24h），但大多数患者在CSF中维持HIV-1 RNA。应考虑CSF中的ATV PK数据，并且建议使用这种双药简化方案确保有效的CSF病毒抑制。

著录项

来源
《Journal of neurovirology》 |2018年第4期|共7页
作者
Arkaitz Imaz; Jordi Niubó; Alieu Amara; Saye Khoo; Elena Ferrer; Juan M Tiraboschi; Laura Acerete; Benito Garcia; Antonia Vila; Daniel Podzamczer;
展开▼
作者单位

HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;

Department of Microbiology Bellvitge University Hospital-IDIBELL;

Department of Molecular and Clinical Pharmacology Institute of Translational Medicine University;

Department of Molecular and Clinical Pharmacology Institute of Translational Medicine University;

HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;

HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;

HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;

HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;

HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;

HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学;
关键词
HIV-1; Antiretroviral therapy; Cerebrospinal fluid; Atazanavir; Lamivudine;

机译：HIV-1;抗逆转录病毒治疗;脑脊液;ATAZANAVIR;拉米夫定;

相似文献

外文文献
专利

1. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39) [J] . Arkaitz Imaz, Jordi Niubó, Alieu Amara, Journal of neurovirology . 2018,第4期

机译：脑脊液液体浓度和病毒抑制在HIV-1感染患者中接受Ritonavir-Boosted Atazanavir Plus Lamivudine双抗逆转录病毒治疗（西班牙艾滋病毒/艾滋病研究网络，Prec / Ris 39）
2. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40) [J] . Imaz Arkaitz, Niubo Jordi, Cottrell Mackenzie L., Clinical infectious diseases . 2019,第8期

机译：与Tenofovir Alafenainide相比，精英替诺维尔浓度，病毒抑制和精液质量，与替诺福韦解毒型（西班牙艾滋病毒/艾滋病研究网络，Prec / Ris 40）相比
3. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. [J] . Squires KE, Young B, Dejesus E, AIDS . 2010,第13期

机译：与阿扎那韦/利托那韦相比，阿扎那韦的疗效和耐受性相似，在用艾滋病毒感染的患者中，先用阿巴卡韦/拉米夫定加利托那韦增强的阿扎那韦对阿扎那韦/拉米夫定进行初步抑制后，均与阿巴卡韦/拉米夫定相比较。
4. A Hybrid Classification Tree and Artificial Neural Network Model for Predicting the In vitro Response of the Human Immunodeficiency Virus (HIV1) to Anti-Viral Drug Therapy [C] . W. R. Danter, D. Gregson, K. A. Ferguson, ANNIMAB-1 Conference . 2000

机译：一种混合分类树和人工神经网络模型，用于预测人免疫缺陷病毒（HIV1）对抗病毒药物治疗的体外反应
5. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
6. Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial Corrigendum [O] . 2017

机译：从Atlas-M试验的数据开始对意大利接受基于atazanavir的三联疗法的HIV阳性患者简化为atazanavir + ritonavir +拉米夫定双重疗法的预算影响分析更正
7. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy [O] . Gisolf E. H., van Praag R. M., Jurriaans S., 2000

机译：尽管在接受抗逆转录病毒疗法的HIV-1感染患者中脑脊液HIV RNA未被检测到，但脑脊液趋化因子浓度仍在增加

Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)

摘要

著录项

相似文献

相关主题

期刊订阅